Tyrosine Kinase Inhibitors
The following drugs under development are similar to approved GIST treatments imatinib (Gleevec) and sunitinib (Sutent) in that they inhibit the KIT and/or PDGFR growth factor receptors. Some of them also inhibit vascular endothelial growth factor (VEGF) or its receptors for anti-angiogenic effects.